Chimera Bioengineering is focused on developing innovative cell therapies that target cancer at the cellular level, aiming to improve patient outcomes while minimizing the harmful effects associated with traditional treatments like chemotherapy. Their approach centers on engineering T-cells, which are crucial components of the immune system, to recognize and attack tumor cells specifically. By harvesting and modifying these immune cells to express chimeric antigen receptors (CARs) that target specific tumor antigens, Chimera's therapies are designed to enhance the immune response against cancer. This method allows for a more precise attack on tumors, potentially leading to better efficacy and reduced toxicity compared to conventional cancer treatments.

To address the challenges faced by current engineered cell therapies, Chimera has developed a suite of proprietary technologies that enhance control over T-cell behavior and payload expression. Their GOLD PLATFORM™ enables precise regulation of gene expression, while the MERCURY™ system allows for fine-tuning of CAR expression levels to optimize therapeutic activity and minimize side effects. Additionally, Chimera's advanced vector design integrates multiple elements of control into a single vector, streamlining the manufacturing process. By focusing on these innovative solutions, Chimera aims to create safer and more effective therapies for both solid tumors and blood cancers, ultimately transforming the landscape of cancer treatment.

United States

Chimera's mission is to reprogram life to end cancer, using therapies that restore dignity to patients.  We do this with next generation, safer and more potent, CAR T therapeutics.

Chimera Bioengineering

Company Details